NeurologyLive® Friday 5 — May 2, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Advancing MS Research Through Recognition and Innovation: The John Dystel Prize

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

2: Illuminating Genetic Insights in Parkinson Disease Through PD GENEration: James Beck, PhD

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

3: Prioritizing Brain Health in NMOSD Beyond Disease-Modifying Therapies: Sumaira Ahmed

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]

4: NeuroVoices: Stewart Tepper, MD, on Newly Approved Digital Therapeutic for Preventive Migraine

Renowned migraine specialist Stewart Tepper, MD, highlighted the groundbreaking FDA approval of CT-132, the first digital therapeutic for migraine prevention, and what it means for clinicians, patients, and future care models.

5: Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.